C Diff Foundation is proud to present the 2014 "Raising C.difficile Awareness" conference. Join us November 4th at 8 a.m. – 5 p.m. at the University of Illinois at Chicago, Student Center, West 828 S. Wolcott Avenue, Thompson Room, Chicago, IL. World renowned topic experts will be presenting data for C. difficile and Hospital-Acquired Infection (HAI) prevention, treatments, and environmental safety. To view the conference details, guest speaker information, and register online visit the website www.cdifffoundation.org - Contact Nancy C. Caralla, Executive Director for additional information (919) 201-1512.
We take this opportunity to thank our Corporate Sponsors for partnering with the Foundation in "Raising C. difficile Awareness" worldwide. Seal Shield™ develops infection control technologies that help prevent infections and save lives. Seal Shield's unique combination of waterproof electronics with antimicrobial product protection and FDA approved air purification solutions combine to create the most complete infection control solutions available. Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the US and Canada Cubist markets DIFICID ® (fidaxomicin) for the treatment of Clostirdium difficile-associated diarrhea (CDAD).Cubist is conducting a Phase 3 program for surotomycin, a potential treatment for diarrhea caused by Clostridium difficile. Altapure's Model HJ-30i ™ is an advanced ultrasonic product capable of delivering a dense cloud of sub-micron droplets for the high-level disinfection of large spaces such as those found in a typical hospital. HJ-30i provides a 100% kill of all spores, viruses, and bacteria. Sanofi Pasteur, the vaccines division, is the largest company entirely dedicated to vaccines, investing more than EUR 1 million in research and development every day. Sanofi Pasteur is investigating a vaccine to prevent C. difficile infection, with a phase III efficacy trial called Cdiffense underway in 16 countries across 5 continents. Clorox Healthcare, with a century of experience, knowledge, and innovation to achieve a single goal, save lives, Clorox Healthcare strives to continually develop comprehensive solutions that help eliminate healthcare-associated infections wherever they are.
Researchers uncover key mechanisms of CRISPR gene editing